A recent genome-wide gene study analyzing the interaction of cardiovascular and cerebrovascular risk factors (CVRFs) identified a key gene, FMNL2, whose expression is evident in the brains of individuals with cerebral infarcts and AD pathology and is correlated with amyloid and phosphorylated tau accumulation. Here, MAPT is linked to Alzheimer disease.